Ir al contenido principal
← Toda la financiación verificada
Nivel AUS

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)

National Institutes of Health

Inicia sesión y completa tu Funding Passport para ver si calificas — un veredicto transparente basado en reglas, no una caja negra.

Iniciar sesión

Sobre esta oportunidad

The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this announcement is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.

Documentos requeridos

La fuente oficial no indica documentos específicos aquí — confirme los requisitos antes de postular.

Fuente y trazabilidad de verificación

Primera obtención
20 de noviembre de 2026
Última verificación
20 de noviembre de 2026
Huella del contenido
c5331377760e3a46…